| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | 坪井 光弘
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | 近藤 和也
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 滝沢 宏光 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.胸部・内分泌・腫瘍外科学]/[徳島大学.病院.診療科.外科.呼吸器外科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | 河北 直也 ([徳島大学.大学院医歯薬学研究部.医学域.先端医学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.胸部・内分泌・腫瘍外科学]/[徳島大学.病院.診療科.外科.呼吸器外科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 5. | 澤田 徹
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 6. | 鳥羽 博明 ([徳島大学.大学院医歯薬学研究部.保健学域.保健科学部門.看護学系.臨床腫瘍医療学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | 川上 行奎
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | 吉田 光輝
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 9. | (英) Ishikura Hisashi (日) 石倉 久嗣 (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 10. | (英) Kimura Suguru (日) 木村 秀 (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 11. | 丹黒 章
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Adjuvant chemotherapy with uracil tegafur (UFT) improved survival among patients with completely resected stage I lung adenocarcinoma. S-1, an oral dihydropyrimidine dehydrogenase (DPD)-inhibitory 5-fluorouracil, is a more potent DPD inhibitor than UFT;therefore, we hypothesized that postoperative adjuvant chemotherapy with S-1 would be effective for advanced non-small cell lung cancer (NSCLC). We conducted a feasibility study of S-1 as postoperative adjuvant chemotherapy in patients with curatively resected pathological stage bold I back 10 bold I and bold I back 10 bold I back 20 bold I A NSCLC. Adjuvant chemotherapy consisted of 9 courses (4-week administration, 2-week withdrawal) of S-1 at 80-120 mg/body per day. Twenty-four patients with completely resected NSCLC were enrolled in this study from November 2007 through December 2010. The primary endpoint was the rate of completion of the scheduled adjuvant chemotherapy. The secondary endpoints were safety, overall survival, and relapse-free survival. Five patients were censored because of disease recurrence. The planned 9 courses of S-1 were administered to completion in 8 patients. Twelve patients completed more than 70% of the planned courses. Grade 3 adverse reactions, such as elevated total bilirubin (4.2%) and pneumonitis (4.2%), were observed, but there were no Grade 4 adverse reactions. Patients who completed more than 70% of the 9 courses demonstrated better overall survival than those who completed less than 70%. Postoperative administration of S-1 may be possible with few severe adverse events as adjuvant chemotherapy for patients with curatively resected pathological stage bold I back 10 bold I -bold I back 10 bold I back 20 bold I A NSCLC. J. Med. Invest. 65:90-95, February, 2018. (日)
| [継承] |
| ○キーワード (推奨): | 1. | (英) Aged (日) (読)
| [継承] |
| 2. | (英) Carcinoma, Non-Small-Cell Lung (日) (読)
| [継承] |
| 3. | (英) Chemotherapy, Adjuvant (日) (読)
| [継承] |
| 4. | (英) Drug Combinations (日) (読)
| [継承] |
| 5. | (英) Feasibility Studies (日) (読)
| [継承] |
| 6. | (英) Female (日) (読)
| [継承] |
| 7. | (英) Humans (日) (読)
| [継承] |
| 8. | (英) Lung Neoplasms (日) (読)
| [継承] |
| 9. | (英) Male (日) (読)
| [継承] |
| 10. | (英) Middle Aged (日) (読)
| [継承] |
| 11. | (英) Neoplasm Staging (日) (読)
| [継承] |
| 12. | (英) Oxonic Acid (日) (読)
| [継承] |
| 13. | (英) Tegafur (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | The Journal of Medical Investigation : JMI ([徳島大学.医学部])
(pISSN: 1343-1420, eISSN: 1349-6867)
| ○ISSN (任意): | □ | 1349-6867
ISSN: 1343-1420
(pISSN: 1343-1420, eISSN: 1349-6867) Title: The journal of medical investigation : JMITitle(ISO): J Med InvestSupplier: 徳島大学Publisher: University of Tokushima (NLM Catalog)
(Webcat Plus)
(医中誌Web)
(J-STAGE)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 65
| [継承] |
| ○号 (必須): | □ |
| [継承] |
| ○頁 (必須): | □ | 90 95
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2018年 0月 初日 (平成 30年 0月 初日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.2152/jmi.65.90 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 29593202 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): | □ | 2-s2.0-85044443235
| [継承] |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Article.ELocationID: 10.2152/jmi.65.90 (日)
| [継承] |
| 2. | (英) Article.PublicationTypeList.PublicationType: Journal Article (日)
| [継承] |
| 3. | (英) KeywordList.Keyword: Non-small cell lung cancer (日)
| [継承] |
| 4. | (英) KeywordList.Keyword: S-1 (日)
| [継承] |
| 5. | (英) KeywordList.Keyword: adjuvant chemotherapy (日)
| [継承] |
| 6. | (英) KeywordList.Keyword: feasibility study. (日)
| [継承] |